Multifocal motor neuropathy

Multifocal motor neuropathy, or MMN, is a long-term condition affecting motor nerves. These nerves carry signals from the brain and spinal cord to the muscles. When their signals are interrupted, muscles become weak.

“Multifocal” means that separate nerves in different areas are affected. Weakness is usually uneven, affecting one side or limb more than another. It often begins in a hand, forearm, lower leg, or foot.

MMN usually develops slowly. It mainly affects movement rather than sensation, so significant numbness, tingling, or pain is not typical.

The condition matters because untreated weakness may gradually interfere with walking, gripping objects, working, and everyday tasks. MMN can sometimes resemble other nerve or motor neuron conditions, including amyotrophic lateral sclerosis, or ALS. Unlike ALS, MMN is an immune-related peripheral nerve condition and often responds to immunoglobulin treatment.

Weakness is the main symptom. It may develop gradually over months or appear in small steps. The areas affected can differ greatly from person to person.

Common features include:

• Weak grip, difficulty turning keys, or frequently dropping objects
• Hand or finger weakness, sometimes causing difficulty straightening the fingers
• Foot drop, in which the front of the foot is difficult to lift
• Muscle cramps, twitching, or visible rippling under the skin
• Reduced muscle bulk after weakness has been present for some time
• Reduced reflexes in the affected limb

Symptoms are usually asymmetric, meaning the two sides of the body are not affected equally. The arms, especially the hands and forearms, are often affected earlier than the legs.

Sensation is usually preserved. Persistent numbness, marked tingling, or loss of feeling is not typical and may point to another condition that also needs assessment.

Muscles involved in eye movement, speech, swallowing, and breathing are usually spared. However, any new breathing or swallowing difficulty needs urgent medical attention, whatever the suspected cause.

MMN is thought to happen when the immune system mistakenly targets parts of the motor nerves. This disrupts the electrical signals travelling to the muscles.

Some people have antibodies against a nerve component called GM1 ganglioside. Antibodies are proteins made by the immune system. Finding anti-GM1 antibodies can support the diagnosis, but many people with MMN do not have a positive result. A negative test does not rule it out.

The reason this immune response begins is not fully understood. MMN is not caused by exercise, diet, stress, or something a person has done.

It is not contagious. It is also not usually considered an inherited condition, and there is no established pattern of it passing from parent to child. No clear lifestyle-related risk factors have been identified.

There is no single blood test that confirms MMN. Diagnosis is based on the pattern of symptoms, a neurological examination, and electrical tests of the nerves and muscles.

A neurological examination checks muscle strength, reflexes, coordination, and sensation. The pattern of weakness helps distinguish MMN from conditions affecting muscles, the spinal cord, or motor neurons.

Nerve conduction studies send small electrical signals along selected nerves. A key finding is conduction block, meaning that a motor nerve signal is reduced or stopped as it travels along part of a nerve. Doctors look for this away from common pressure points, where temporary nerve compression can produce similar findings.

Electromyography, or EMG, measures electrical activity within muscles using a thin needle electrode. It can show how reduced nerve signals are affecting the muscles.

Blood tests may include anti-GM1 antibodies and tests for other possible causes of weakness. Depending on the findings, an MRI scan or a lumbar puncture may be used to investigate other conditions. A lumbar puncture collects a small sample of the fluid surrounding the brain and spinal cord.

MMN can be difficult to identify early, particularly if conduction block is not captured on the first study. Repeat testing or assessment by a neurologist with experience in peripheral nerve conditions may be needed.

The main treatment is immunoglobulin therapy. Immunoglobulin contains antibodies collected and purified from donated human plasma. It changes how the immune system acts on the nerves.

Treatment is usually given into a vein as intravenous immunoglobulin, or IVIg. Many people improve or become more stable with IVIg, but the response is not identical for everyone. Benefits may wear off, so repeated treatment is often needed. The timing is adjusted according to strength, daily function, side effects, and how long the benefit lasts.

Possible short-term effects of IVIg include headache, tiredness, chills, nausea, or an infusion reaction. Less common but more serious problems include blood clots, kidney injury, breakdown of red blood cells, or inflammation around the brain. Health professionals assess individual risks and monitor treatment.

Some people who are stable on IVIg may use immunoglobulin injected under the skin, called subcutaneous immunoglobulin, for maintenance treatment. Whether this is suitable depends on local availability, treatment response, and specialist assessment.

Other immune-suppressing treatments have been studied, but evidence for many of them is limited. Some carry substantial risks. Corticosteroids and plasma exchange, which help certain other inflammatory nerve conditions, generally do not help MMN and may worsen weakness.

Rehabilitation can help you use your strength safely and remain independent. It may include:

• Physiotherapy to support mobility, balance, and comfortable movement
• Occupational therapy for hand function, work, and daily activities
• A brace or splint for foot drop or hand weakness
• Practical changes to reduce falls and make tasks easier

Exercise is usually encouraged within personal limits. Repeated activity that causes prolonged exhaustion or loss of function may need to be modified.

Weakness may become more persistent if nerve signals remain disrupted. Over time, some muscles can shrink, a process called muscle wasting or atrophy. Long-standing weakness can also reduce joint movement or alter the way you walk.

Hand weakness may affect writing, dressing, cooking, or work involving tools. Foot drop can increase the chance of tripping and falling.

Treatment can reduce these effects, but it may not restore strength that has been lost for a long time. Complications from immunoglobulin are uncommon but require monitoring, particularly during repeated treatment.

There is no known way to prevent MMN. It is not linked to a particular lifestyle, infection, or avoidable exposure.

Early assessment of unexplained, uneven weakness may allow treatment to begin before more function is lost. This does not prevent the condition itself, but it may help limit its effects.

Using recommended braces, adapting activities, and addressing fall risks can help prevent injuries caused by weakness.

MMN usually follows a long-term course over years. Weakness may progress slowly, worsen in steps, or remain stable for periods. The course cannot be predicted precisely for one person.

Many people need ongoing immunoglobulin treatment. Some notice a clear cycle in which strength improves after an infusion and fades before the next one. Others mainly experience stabilisation rather than an obvious improvement.

Treatment can help many people remain active and independent. However, some gradually accumulate weakness despite treatment, particularly in muscles that were affected before therapy began. Regular strength and function assessments help show whether treatment remains effective.

MMN generally does not shorten life expectancy. Breathing, swallowing, thinking, bowel and bladder control, and sensation are usually preserved. Daily life may still require adjustments for hand weakness, reduced walking ability, treatment appointments, or fatigue related to effort.

Routine follow-up with a neurology team is important. Reviews may include strength testing, discussion of daily function, and changes to the timing or form of immunoglobulin treatment.

Arrange a routine medical assessment if you develop gradually increasing weakness, particularly if it affects one hand, arm, foot, or leg more than the other. Examples include repeated tripping, new foot drop, difficulty opening containers, or frequently dropping objects.

If you have already been diagnosed with MMN, contact your care team promptly if:

• Weakness is clearly increasing or treatment benefits are wearing off earlier
• Falls are becoming more frequent
• A brace no longer fits or causes skin damage
• Treatment causes persistent headache, vomiting, rash, reduced urination, or unusual fatigue

Seek emergency help for new difficulty breathing or swallowing, rapidly spreading severe weakness, fainting, chest pain, or signs of a severe allergic reaction such as facial swelling and breathing difficulty.

Sudden facial weakness, speech difficulty, or one-sided weakness may be signs of a stroke rather than MMN. Seek emergency help immediately for these symptoms.

Is multifocal motor neuropathy the same as ALS?

No. Both can cause weakness, cramps, twitching, and muscle wasting, but they affect the nervous system differently. MMN affects peripheral motor nerves and usually responds to immunoglobulin. ALS affects motor neurons and does not produce the same pattern of motor nerve conduction block. Careful nerve testing helps distinguish them.

Can multifocal motor neuropathy be cured?

There is currently no cure. Immunoglobulin can improve strength or slow further loss of function, but it usually does not remove the underlying tendency for immune-related nerve injury. Many people need long-term treatment.

Why do I have weakness but little or no numbness?

MMN mainly affects motor nerves, which control muscles. Sensory nerves carry information about touch, pain, and temperature and are usually spared. This is why weakness can be significant while feeling remains normal.

Will I need IVIg forever?

Many people need ongoing treatment because the benefit wears off when therapy is stopped or delayed. The dose and schedule are reviewed over time. Some people can use subcutaneous treatment, while others need continued intravenous infusions. Treatment should not be stopped without specialist guidance.

Can I exercise with MMN?

Most people can exercise, and appropriate activity can support mobility, fitness, and joint movement. The level needs to match your strength and balance. A physiotherapist can help plan activity that avoids falls and prolonged overwork of weak muscles.

Can MMN affect breathing?

Breathing muscle involvement is uncommon in MMN. New shortness of breath should not be assumed to be part of the condition. Sudden or severe breathing difficulty requires emergency assessment.